Biotek-snakken — December 2025
-
Dårligt nyt fra Cantargia. https://cantargia.com/en/press-releases/cantargia-provides-update-on-overall-survival-data-from-trifour
-
Godmorgen
-
PARETO SER FÖRSTÄRKT FÖRHOPPNING BI-1808 NÅR MARKNAD
PARETO SER FÖRSTÄRKT FÖRHOPPNING BI-1808 NÅR MARKNAD | Placera.se
PARETO SER FÖRSTÄRKT FÖRHOPPNING BI-1808 NÅR MARKNAD
placera.se (www.placera.se)
"Pareto upprepar sin köprekommendation för Bioinvent med en riktkurs på 134 kronor."
-
BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
-
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday,
Yahoo Finance (finance.yahoo.com)
-
-
LP90 / Darvin (o.a): Curasight, fra Q3 rapporten 27. Nov.: To support and accelerate the strategic business
development, discussions are currently ongoing with a number of major pharma companies with a view to uncover opportunities and interest in uTRACE
and uTREAT. -
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 infla
Yahoo Finance (finance.yahoo.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind